所有图片(1)

文件

1478800

USP

奥利司他

Name: 奥利司他
Brand: USP

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

N-甲酰基-L-亮氨酸（1S）-1 - [[（2S，3S）-3-己基-4-氧代-2-氧杂环丁烷基]甲基]十二烷基酯, Ro-18-0647, （−）-四氢脂抑素

经验公式（希尔记法）:

C₂₉H₅₃NO₅

CAS号:

96829-58-2

分子量:

495.73

MDL编号:

MFCD05662360

PubChem化学物质编号:

329750618

NACRES:

NA.24

等级

pharmaceutical primary standard

API family

orlistat

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

格式

neat

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

human ... LIPF(8513) , PNLIP(5406)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

生化/生理作用

奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他说明

溶液不完全澄清，小颗粒可能仍然悬浮。

Sales restrictions may apply.

1478833

三苯基氧膦, United States Pharmacopeia (USP) Reference Standard

1478811

1478844

1478855

1478822

1680685

三丁基氧化膦, United States Pharmacopeia (USP) Reference Standard

PHR2544

三苯基氧膦, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2543

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.

Walmir Coutinho

Arquivos brasileiros de endocrinologia e metabologia, 53(2), 262-270 (2009-05-26)

Ancillary therapies for weight management, consisting mainly of diet and exercise programs that incorporate variable levels of lifestyle modification techniques, are frequently ineffective to achieve clinically meaningful weight loss and maintenance. Although pharmacological treatment of obesity is widely used in

[The role of orlistat in the treatment of obesity].

György Paragh et al.

Orvosi hetilap, 146(11), 493-498 (2005-04-09)

The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need

Orlistat: a review of its use in the management of obesity.

Sheridan Henness et al.

Drugs, 66(12), 1625-1656 (2006-09-08)

Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data

Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage.

James W Anderson

Expert opinion on pharmacotherapy, 8(11), 1733-1742 (2007-08-10)

Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss

Orlistat: Current issues for patients with type 2 diabetes.

Juliet M Mancino

Current diabetes reports, 6(5), 389-394 (2006-11-02)

Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件